Interview – Accera next up in Alzheimer’s disease

28
Nov

By: Jonathan Gardner  Date: November 25, 2016

Lilly’s solanezumab might have blown up and erased $11bn in market capitalisation this week, but the potential reward from delivering a disease-modifying drug in Alzheimer’s disease is too attractive for many companies to ignore.

Colorado-based Accera could have the next major data point in the space: readout of an early phase III trial of a treatment designed to feed impaired brain cells rather than limiting the damage from amyloid plaque, as most of the big pharma projects seek to do. “As of yesterday morning there were nine companies in phase III, and now there are eight in phase III, and only a handful of these are doing this with non-amyloid antibodies,” chief executive Charles Stacey tells EP Vantage in the wake of the solanezumab readout.

Read full article at: http://www.epvantage.com/Universal/View.aspx?type=Story&id=673527&isEPVantage=yes&notSub=false

 

X